Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SERIES: SEquencing Sacituzumab Govitecan AfteR T-DXd In ER+/HER2 LOW/ULTRA LOW MetaStatic Breast Cancer

NCT06263543 is registered in ClinicalTrials.gov with Reshma L. Mahtani, D.O. as lead sponsor.

NCT NCT06263543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06263543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SERIES: SEquencing Sacituzumab Govitecan AfteR T-DXd In ER+/HER2 LOW/ULTRA LOW MetaStatic Breast Cancer
Lead sponsor
Reshma L. Mahtani, D.O.
Phase
Phase 2
Overall status
Recruiting
Start date
June 17, 2024
Completion date
December 31, 2028
Enrollment
75 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, hormone-receptor-positive breast cancer, human epidermal growth factor 2 low breast cancer, metastatic breast cancer